Podcasts about OTC

Anhören, lachen, abstimmen! Von 1LIVE.

Anhören, lachen, abstimmen! Von 1LIVE.

In today's episode the gang is back!!! Nando T and the OTC are loving wrestling, Arianna brings some fantastic storylines to the table during You Just Made the List!!! We get into current news, smackdown, RAW and AEW!!! CHEERS!!!JERKING THE CURTAINROUND TABLE OF TOPICSNEWSKeith Lee expected to be done with wrestling, Michin announces divorce Wyatt's returning to WWE???“You Just Made the List” Give me a storyline for Baron Corbin SMACKDOWNNick Aldis is back and introduces his new Champ Cody and Punk for SummerSlam!!! Let's goooo, can't wait for those promos Finn vs Tala Tonga gets me excited Truth protecting Keyes is interesting Fatu vs Solo at SummerSlam…..book it The Bloodline family is dysfunctional at best, is Jimmy dropping hints for a Naomi return???Johnny Wrestling is the voice of the voiceless This Charlotte vs Jade is cooking……hopefully Alexa Bliss gets back TWISTED Baron Corbin!?! Very interested in seeing how he mixes with Trick Williams…..great to see End of Days Gunther snaps…..Aldis and Gunther is happening RAWBrock continues the head games with Oba, the hype is real Iyo NEEDS to beat Liv at Summerslam!!! Otis my guy, why lower yourself to Maxxine??? You had Mandy Rose for crying out loud I hate to say it but the Vision got one over on this crowd…..that was some heat Jacob aging fast in the Bloodline, looking like an elder Let's goooo Solo and LA Knight working together……YEAHHHHREALLY!?! Maxxine replacing Heyman Who was AP talking to???The Shield vignettes are nostalgic and the perfect recipe for Seth vs Roman What the fudge happened to Lyra!?! Lawwwd have Mercy…..what a great exchange Big Cass returns 8/3, where's Enzo???Wow Joe Hendry!!!Gable vs Penta moves the needle 14 YEARS!!! Round 1 goes to Roman in the verbal judo…..this is so fucking good right now!!! Drinking all them pitchers of kool aid TNA10 count with Always Ready AriannaCheck out the Smackdown Siblings on TikTok @ariannaandthomasFollow us on TikTok @the.funkaholiks.podEpisodes dropping weekly!!! THEE POD THAT TALKS WHAT THEY LOVE 

En Capital Intereconomía, en Empresas con Identidad, hablamos con Marc Pagès, director general de Skello en España, una de las compañías tecnológicas europeas con mayor crecimiento en soluciones para la planificación y gestión de equipos operativos, que acaba de cerrar una ronda de financiación de 200 millones de euros. Durante la entrevista conocemos el modelo de negocio de Skello, cómo ayuda a las empresas a optimizar la gestión de sus plantillas y qué supone esta importante operación de financiación para acelerar su crecimiento y expansión internacional. También analizamos los retos del mercado laboral, la digitalización de los procesos de recursos humanos y el papel de la inteligencia artificial en la organización del trabajo. En Digital Business hablamos con Salvador Mas, CEO de GPTadvisor, para analizar la actualidad del sector tecnológico, marcada por la celebración de un gran evento de innovación y por la petición del Banco Central Europeo a las entidades financieras para que presenten un plan de acción frente a la amenaza que representa el proyecto Mythos. También contamos con Javier Pastor, Head of OTC de Bit2Me, para analizar la actualidad del mercado de los activos digitales. Ponemos el foco en la denominada Crypto Week y en la tramitación de la Ley CLARITY en Estados Unidos, una regulación llamada a definir el marco jurídico de los criptoactivos y que podría marcar un antes y un después para el desarrollo del sector. Y terminamos con Borja Martín de la Torre, cofundador y COO de Meritoo (Remove Group), con quien abordamos la gestión de las crisis reputacionales en las empresas. Analizamos los errores más habituales cuando estalla una crisis, el papel del liderazgo, la importancia de reaccionar a tiempo y cómo una gestión transparente y responsable puede ayudar a recuperar la confianza y reforzar la reputación de una organización.

Anhören, lachen, abstimmen! Von 1LIVE.

Anhören, lachen, abstimmen! Von 1LIVE.

When sunny summer days come around, it makes some dermatologists shudder. They would prefer we behave like bats and hide in caves until nightfall. Failing that, they stress the importance of always applying (and re-applying) high SPF sunscreen, wearing sun-blocking clothing with long sleeves and keeping a big-brimmed hat firmly on the head. A beekeeper's outfit might be perfect. But must you really shun the sun completely to save your skin? Our guest describes how to practice moderation safely. He also explains why some people are addicted to sunshine, while others are allergic to it. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, July 11, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on July 13, 2026. Can You Really Be Addicted to Sunlight? Dermatologists do their best to discourage people from using tanning beds. They describe the damage that ultraviolet light can cause, ranging from wrinkles to skin cancer. For some people, though, those arguments just don't make a difference. Our guest, Dr. Steve Feldman, conducted a study several years ago. The volunteers were accustomed to using tanning beds. In the study, there were two beds, one with the usual ultraviolet light and the other, identical in appearance and temperature, had its UV blocked. After a session in each bed, volunteers were allowed to choose their bed for the last session. They almost invariably chose the bed with the active UV. To follow up, the researchers administered naltrexone, the opioid-blocking medication. When volunteers had taken it, they were no longer able to distinguish which bed was active. It seems that, for these people, ultraviolet light activates pro-opiomelanocortin, which in turn triggers the production of natural opioids called endorphins. Further research imaging the brain during tanning sessions confirmed that the UV exposure was activating areas of the brain associated with pleasure (Psychiatry Research. Neuroimaging, May 30, 2016).  Dr. Feldman and a colleague found that excessive indoor tanning is similar in pattern to substance use disorders (Journal of Cutaneous Medicine and Surgery, May-June 2025). Can You Save Your Skin and Still Enjoy the Outdoors? Dr. Feldman offers advice on avoiding sunburn that is tempered with this fact from epidemiology: people who go out in the sun live longer (International Journal of Environmental Research and Public Health, July 13, 2020).  The goal here is not to shun the sun completely, but rather to exercise enough caution and good judgment to avoid burning your skin. (Who wants to burn, anyway? It hurts, and it looks bad.) Timing your sun exposure carefully is crucial to save your skin from sunburn. You may also be interested in the new sunscreen ingredient the FDA just approved, bemotrizinol. What Can You Do About Heat Rash? When the weather gets hot and bodies get sweaty, heat rash becomes a common complaint. Sweaty skin may develop bumps that can sometimes be very itchy. What do you do to ease the discomfort? If you can cool the skin off, it might help a lot. Of course, people may also suffer from other types of rash. Babies get diaper rash. Women sometimes experience under-breast rash, just as men may develop jock itch. Zinc oxide ointment can often be helpful for these types of rash. Managing Psoriasis Psoriasis is one of Dr. Feldman's special research interests. The red scaly plaques of this skin condition have raised borders. They look a lot like a fungal infection, but there is no fungus present on the skin to cause them. Something else seems to trigger the skin's immune system to react along the same pathways as if there were a fungus. Most of the time, psoriasis is mild enough to manage without costly medications. It actually responds very well to ultraviolet light exposure. UV downregulates the immune system's over-response. While many dermatologists offer UV exposure within their office walls, in the summertime patients could get exposure to sunlight outdoors. This is practical if they avoid the middle of the day, when they might get burned. Another option? Tanning beds also offer an easy way to calibrate the appropriate amount of UV exposure to save your skin from psoriasis. (Most dermatologists don't approve of this one, so don't tell.) One other practical but unorthodox tip for dealing with mild psoriasis. OTC cortisone may not be strong enough to help heal up a red spot. But you could buy Flonase nasal spray or a generic version, fluticasone, over the counter. Spray it on your skin and appreciate the relief. In fact, this could work for a mild case of poison ivy or other skin irritation as well. Severe cases still need a dermatologist's care. What to Do About Atopic Dermatitis Atopic dermatitis is the medical term for eczema. People with allergies or asthma also appear to be more vulnerable to eczema. Dysregulation of the immune mediators interleukin 4 (IL4) or IL13 may be responsible. This condition may appear in a mild form, which can be readily managed, or a more severe form that might require prescription medication. A topical corticosteroid such as triamcinolone will often clear it up. Or you could try spraying on some Flonase nasal spray for a cost-effective low-key approach. Those will actually help the majority of people with mild eczema. Using mild soap rather than detergent-based body wash, moisturizing well and following an anti-inflammatory diet are the pillars of home management. People with more severe atopic dermatitis covering a large portion of the body may need powerful prescription medication rather than topical steroids. Trying to cover so much skin with steroid would probably result in side effects from the cream. Dupixent (dupilumab) is a relatively new self-injectable medication that blocks IL4 and IL13. It works well for most people with atopic dermatitis and has a good safety profile. Certain other drugs in this category, such as Skyrizi (risankizumab), are also pretty safe but very pricey. Stelara (ustekinumab), has been around longer. Biosimilars for Stelara have been approved and are more affordable. Ustekinumab blocks IL12 and IL23. TV ads tout other medicines for this condition as well. Rinvoq (upadacitinib) is three or four times more effective than Dupixent, but it is also super expensive. It is a Janus-kinase (JAK) inhibitor. Xeljanz (tofacitinib) is another potent prescription JAK inhibitor, but it carries an elevated risk of heart attack. Beware of Bug Bites Another summer skin hazard is bug bites. Here unquestionably the best approach to save your skin is avoidance. Appropriate clothing is key. (That beekeeper's suit will come in handy here again.) Dr. Feldman recommends spraying DEET on your pants legs, socks and sleeves rather than directly on your skin. If there are grasses or brush where you have walked, run or played, a tick check immediately upon coming inside is critical. Can AI Help Patients with Skin Problems? It doesn't make sense to tell people to stay off the internet. Some searches can be quite helpful and guide patients in asking their dermatologist the right questions. Dr. Feldman is enthusiastic about DermNet, a New Zealand dermatology website. https://dermnetnz.org  Joe and Terry recommend SkinSight. This Week’s Guest Steven R. Feldman, MD, PhD, is Professor of Dermatology, Pathology, and Social Sciences & Health Policy, at the Wake Forest University School of Medicine.  His research has been published in over 1,000 peer reviewed, Medline-referenced articles. Expertscape.com ranks Feldman among the top experts in the world on psoriasis, acne, dermatology, and treatment adherence. Steve Feldman, MD, in Dermatology clinic, Country Club Commons Listen to the Podcast The podcast of this program will be available Monday, July 13, 2026, after broadcast on July 11. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Amid elevated volatility and rapid advances in technology, systematic trading is gaining steam in commodities markets. Join Leland Price from the FICC Market Structure & Liquidity Strategy team alongside commodity traders Max Lee and Biko Agozino as they discuss what's driving the growth of quantitative strategies across commodities and what it means for market participants today. Explore how automation is unlocking access to OTC liquidity, alpha opportunities emerging from inefficiency as well as how API connectivity and AI are shaping the modern trader's toolkit.   This episode was recorded on June 25, 2025.   The views expressed in this podcast may not necessarily reflect the views of JPMorgan Chase & Co, and its affiliates, together J.P. Morgan, and do not constitute research or recommendation advice or an offer or a solicitation to buy or sell any security or financial instrument. They are not issued by Research but are a solicitation under CFTC Rule 1.71. Referenced products and services in this podcast may not be suitable for you, and may not be available in all jurisdictions. J.P. Morgan may make markets and trade as principal in securities and other asset classes and financial products that may have been discussed. The FICC market structure publications, or to one, newsletters, mentioned in this podcast are available for J.P. Morgan clients. Please contact your J.P. Morgan sales representative should you wish to receive them. For additional disclaimers and regulatory disclosures, please visit www.jpmorgan.com/disclosures Copyright 2026 JPMorgan Chase & Co. All rights reserved.

As over-the-counter continuous glucose monitors (CGMs) become more common, clinician guidance matters more than ever. In this episode of BackTable Women's Health, Dr. Nicole Faulkner welcomes Dr. Nicholas Canelo, a family medicine physician and founder of the Perlman Wellness CGM program, to discuss how to effectively guide CGM use in OBGYN practice, from preconception and PCOS to pregnancy and perimenopause. They highlight the importance of interpreting data trends, setting realistic glucose targets, and supporting patients through the practical and emotional challenges of CGM use. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction04:58 - CGMs in Women's Health07:33 - OTC Data Sharing Issues09:52 - Pregnancy Glucose Targets16:20 - Accuracy and Variability20:10 - Anxiety and Eating Disorders24:41 - Counseling and Follow-Up28:29 - Prescription and OTC CGM Picks37:24 - False Lows and Sensor Errors41:23 - Alarm Settings and Logging44:06 - Interpreting Metrics and Limits46:44 - Provider Dashboards 48:42 - Final Thoughts --- More about this episode Given the lack of well-established blood glucose targets outside of type 1 diabetes, Dr. Canelo reviews commonly used ranges for individuals without diabetes, those with prediabetes, and pregnant patients with type 1 or 2 diabetes. He explains how to interpret CGM data, including the time in tight range, coefficient of variation, and the importance of focusing on overall trends rather than isolated glucose spikes. They also discuss the potential drawbacks associated with CGM use, including anxiety and eating-disorder risks. Practical considerations include sensor inaccuracies, false lows readings, and optimizing alarm settings. Dr. Canelo emphasizes the importance of having patients log meals and other events while wearing the sensor and scheduling follow-up after the initial 15-day wear period to ensure accurate interpretation and effective counseling. Finally, they compare OTC and prescription CGM options, including costs, clinician access to patient data, and insertion tips. --- Resources Stelo - Over the Counter CGM Optionhttps://www.stelo.com/en-us --- BackTable Women's Health is the go-to podcast for gynecologists, gynecologic surgeons, and other healthcare professionals focused on women's health. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Anhören, lachen, abstimmen! Von 1LIVE.

Anhören, lachen, abstimmen! Von 1LIVE.

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics all about a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com High baseline of general anxiety in pets; fireworks can escalate it dramatically Rough estimates from Dr. Smith: ~30% with noticeable anxiety ~10% with severe reactions: Destruction of property Defecating/urinating in house Extreme escape behaviors (e.g., dog through plate glass window)  Natural vs Pharmaceutical Support & Timing Severe cases: Trazodone often used; Dr. Smith avoids drugs that completely knock pets out Mentions older drugs (e.g., acepromazine) that overly sedate animals She prefers starting treatment the day before fireworks: Anxiety and pain wind up; if you get behind, it's hard to control Natural options she likes: Melatonin, tryptophan, theanine, GABA Pet products that combine several of these Start 1–2 days before fireworks because neighbors often start early [0:18:58]  Melatonin Dosing & CBD for Pets + Environmental Concerns Melatonin for dogs: Start around 3 mg, can go up, even up to ~10 mg in some cases Must be given at bedtime to preserve serotonin/melatonin rhythm Human reference: some serious disease protocols use up to 50 mg CBD: She likes CBD: generally very safe, large margin before toxicity Important: oil directly in mouth, not hidden in food (stomach acid breaks it down) Treats are OK, but observe individual response Ed notes TN hemp rule change (July 1) hurting many businesses; pet CBD appears less restricted for now Environmental side of fireworks: Harm to birds and nocturnal wildlife Startled flocks flying at night, running into obstacles [0:21:57] About CHAI: Services & Ozone Therapy Chai = Chattanooga Holistic Animal Institute On Main Street, Southside Open ~13–14 years Services: Conventional: surgery, X-rays Integrative: herbal medicine, nutrition-first approach, acupuncture, chiropractic Heavy focus on nutrition as foundation Ozone therapy: Used for cancer (mixing with blood + UVB), ear infections (ear cups), GI issues (ozone enema + fecal transplant) Antiviral, antifungal, antibacterial; research supports it but not mainstream due to lack of patentability Ed shares parallel human ozone experiences and enthusiasm [0:24:27] Regulatory Limits on CBD Advice & Practical Dosing Forms California example: Vets cannot legally discuss CBD with clients, while retail hemp shops can freely advise For cats: Liquids in vegetable glycerin are best Alcohol-based tinctures: cats won't like them (foaming, spitting) Liquids can go in food or directly in mouth For dogs: Easier to hide products, but Dr. Smith dislikes many chews: Often have rice flour, tapioca starch, molasses, smoke flavor (potential carcinogen) Prefers powders and liquids [0:26:16] Why Kibble Is Harmful & Heat Safety for Pets Core problems with kibble: Ultraprocessing damages proteins and fats Produces advanced glycation end products (AGEs)—carcinogenic High carbohydrate; not species-appropriate for carnivorous animals Expensive kibble = “expensive Skittles” – processing is still the issue Better options: Raw, dehydrated, freeze-dried Balanced homemade diets Light cooking under ~200°F for seniors to aid digestibility without denaturing nutrients Heat and Summer Safety for Pets Hot ground + hot air → limit daytime walks, adjust exercise Brachycephalic (“smushy-faced”) dogs at special risk: Pugs, Boston Terriers, bulldogs, etc. Shortened face doesn't reduce internal soft tissue; narrow airways = breathing through a straw Heat + humidity = much higher risk of heat exhaustion; many just lie on A/C vents Cats handle heat better (tend to stay inside), but should still be kept cool and supervised Pool safety: pets often don't know how to get out, so human supervision is essential [0:30:41] Independent Practice vs Corporate Vet Medicine CHAI is one of the last independent practices in town Independence allows: Thinking outside the box and the standard “cookbook” Corporate practices: Strict protocols, less flexibility Vets can't always practice as they'd like [0:36:09] Chemical Aging, Peakspan, and Electrolytes Ed quotes Dr. Keith Scott-Mumby (81-year-old MD) on “chemical aging”: Modern environment “poisons” us: Plastics, can linings, pesticides (glyphosate), microplastics Addictive refined carbs, seed oils Many of these mimic hormones and drive accelerated aging “Chemical aging” shows up as: Hair thinning, dry/crepey skin, age spots Persistent belly fat, “man boobs,” fragile bones, poorly fitting clothes Ed's own book: “Are You Sick and Tired of Being Sick and Tired?” He believes it lays out an A–Z game plan for aging better / “peakspan” Available as an ebook on TheHolisticNavigator.com Electrolytes vs Gatorade; Critique of Mainstream Sports Drinks Context: intense summer heat and need for electrolytes Our bodies run on electrical currents (heart, brain, nervous system) regulated by electrolytes Daily potassium need ≈ 3,400 mg Comparison: 20 oz Gatorade: ~75 mg potassium (very low) 0 mg magnesium ~270 mg sodium ~34–36 g carbohydrates/sugar Gatorade Zero: no sugar but uses sucralose, which Ed says can disrupt the gut microbiome Ed's personal take: Would rather “spend” that sugar on a cheesecake dessert than on Gatorade Example True Grace electrolyte formula (carried at Nutrition World): ~750 mg sodium ~250 mg potassium ~100 mg magnesium ~100 mg cordyceps (supportive for lungs/endurance) Great Naturally has ~700 mg potassium per serving Conclusion: many store-brand sports drinks are nutritionally weak and sugar-heavy compared to targeted electrolyte blends [0:44:27] Pepcid (Famotidine), Serotonin, and Essential Oils for Sore Throat Ed introduces Pepcid (famotidine): H2 blocker commonly used OTC for heartburn Prefers it over long-term proton pump inhibitors (e.g., Nexium) Key claim from research Ed cites: Famotidine uniquely blocks certain serotonin activity Can sometimes help with: Chronic pain Inflammation Fatigue Case example: life-threatening serotonin syndrome reversed in 15 minutes with famotidine Elevated serotonin may: Impair mitochondrial energy production Promote chronic inflammation and, paradoxically, some depression and pain Ed has bought a box himself; recommends it as the safer short-term choice for bad heartburn Essential Oils vs Antibiotics for Sore Throats Study on sore throat treatment: 97 adults with clinically diagnosed sore throat Group 1: penicillin twice daily Group 2: oral essential oils capsule 3× daily Group 3: both Outcomes: 100% improvement in antibiotic group 88% improvement in essential oil–only group 100% improvement in combined group Essential oil blend ingredients: Oregano, eucalyptus, lemon, cinnamon, pine oils Clint raises important question: absent a no-treatment control, some percentage may have improved naturally) Quick guide to buying quality beef: Prefer “100% grass-fed” over just “grass-fed” Look for or confirm grass-finished (often not on labels due to cost; best to know your farmer) Beware empty buzzwords: “natural,” “farm raised,” “pasture inspired” Real grass-fed/finished usually costs more due to land/time inputs Fat color: Slight yellow hue suggests carotenoids from real forage [0:53:35] Strength, Independence, and Vitamin D Ed references recent high-production video interview in Atlanta Draws inspiration from Jack LaLanne: Early television fitness and vitamin pioneer Nutrition World once helped bring him to Chattanooga; he lived to ~95 Paraphrased LaLanne theme: Strength gives you options: Carry your own groceries Climb stairs confidently Travel, explore, stay active Play with grandchildren, work in the yard, maintain independence Without strength: Tasks become difficult Confidence drops Independence shrinks; world gets smalle Ed reiterates: muscle is the organ of longevity and needs: Regular weight training Adequate protein Targeted supplementation Discussion of vitamin D: Ed's recent lab: ~54 ng/mL despite summer tan Wants to remain above 50 ng/mL year-round; may increase winter dosing Clint mentions his last check (~3 years ago) was ~70 ng/mL, even before supplementation  The post Radio Show / Podcast – July 5, 2026 first appeared on Vital Health Radio.

Mark Longo sits down with two key executives from Options & Company—Jorge Lobo, Head of Treasury, and Ivyson Vilanova, CFO—for a fascinating look inside Brazil's evolving options marketplace. Options & Company has built its business around improving liquidity, transparency, education, and access for Brazilian options traders. In this conversation, Jorge and Ivyson explain how the firm is helping address some of the biggest challenges facing Brazil's derivatives market while also pursuing ambitious plans for international expansion. The discussion explores the current state of the Brazilian options ecosystem, the dominance of OTC structured products, the need for greater retail investor education, and how Options & Company is working to bring tighter spreads and more efficient markets to investors across Brazil. Mark and his guests also discuss: • The mission and growth of Options & Company • Why options education remains a major opportunity in Brazil • Liquidity challenges in Brazilian listed options • The role of OTC products in the retail marketplace • Brazil's most active sectors and underlying names, including Petrobras, Vale, Itaú, and Nubank • Why international investors are taking a fresh look at Brazil • Plans for Options & Company's expansion into the United States and other global markets • The potential impact of a second Brazilian derivatives exchange • How the Brazilian options market differs from the U.S. market • Why trends like 0DTE and 24-hour trading remain years away from widespread adoption in Brazil

Mark Longo sits down with two key executives from Options & Company—Jorge Lobo, Head of Treasury, and Ivyson Vilanova, CFO—for a fascinating look inside Brazil's evolving options marketplace. Options & Company has built its business around improving liquidity, transparency, education, and access for Brazilian options traders. In this conversation, Jorge and Ivyson explain how the firm is helping address some of the biggest challenges facing Brazil's derivatives market while also pursuing ambitious plans for international expansion. The discussion explores the current state of the Brazilian options ecosystem, the dominance of OTC structured products, the need for greater retail investor education, and how Options & Company is working to bring tighter spreads and more efficient markets to investors across Brazil. Mark and his guests also discuss: • The mission and growth of Options & Company • Why options education remains a major opportunity in Brazil • Liquidity challenges in Brazilian listed options • The role of OTC products in the retail marketplace • Brazil's most active sectors and underlying names, including Petrobras, Vale, Itaú, and Nubank • Why international investors are taking a fresh look at Brazil • Plans for Options & Company's expansion into the United States and other global markets • The potential impact of a second Brazilian derivatives exchange • How the Brazilian options market differs from the U.S. market • Why trends like 0DTE and 24-hour trading remain years away from widespread adoption in Brazil

Transforming your health is more fun with friends! Join Chef AJ's Exclusive Plant-Based Community. Become part of the inner circle and start simplifying plant-based living - with easy recipes and expert health guidance. Find out more by visiting: https://community.chefaj.com/ ORDER MY NEW BOOK SWEET INDULGENCE!!! https://www.amazon.com/Chef-AJs-Sweet-Indulgence-Guilt-Free/dp/1570674248 or https://www.barnesandnoble.com/w/book/1144514092?ean=9781570674242 GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instant-pot-download MY BEST SELLING WEIGHT LOSS BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Get the book here:https://www.amazon.com/shop/chefaj/list/1GNPDCAG4A86S?ref_=aip_sf_list_spv_ofs_mixed_d&ccs_id=ed4dfdad-3f74-40fb-b5ab-b34f9821b312 John Abramson MD, MSc After completing a residency in Family Medicine and a 2-year Robert Wood Johnson fellowship, Dr. John Abramson practiced as a family physician for 20 years in a small town an hour north of Boston. He also served for 7 years as chair of the department of family practice at Lahey Clinic. He was on the Harvard Medical School faculty from 1997-2023, most recently as a Lecturer in the Department of Health Care Policy. In 2002, after becoming aware of the uncorrected misrepresentations about the benefits and dangers of Vioxx and Celebrex in our most respected medical journals, Dr. Abramson left his practice to devote his full attention to researching the quality of the information doctors must rely on. In September 2004 he published Overdo$ed America: The Broken Promise of American Medicine. Just one week later, Vioxx was withdrawn in the biggest drug recall ever, but not before it had killed between 40 and 60,000 Americans, despite providing no better relief than inexpensive OTC anti-inflammatory drugs. From 2005 through the present, Dr. Abramson has continued his research and served as an expert in litigation involving prescription drugs and medical devices, with each case giving him access to millions of pages of confidential corporate documents and unreleased clinical trial data. He has also served as a consultant to the FBI and U. S. Department of Justice, including a case that led to what was, at the time, the largest criminal fine in U.S. history. Dr. Abramson has published multiple articles in peer reviewed journals, made numerous national media appearances, and written many op-ed pieces, including 2 in the New York Times. His main research interest is the extent to which the commercial takeover of medical knowledge, primarily by the drug companies, is compromising the quality of medical information available to even the most dedicated doctors, harming our health, and wasting enormous amounts of Americans' wealth. In February 2022 Dr. Abramson published his second book, Sickening: How Big Pharma Broke American Health Care and How We Can Repair It.

Ever stood frozen in the pharmacy aisle, holding two bottles with no idea which one actually works? You're not alone — and Shanley Chien is here to help. As Senior Health Editor at U.S. News & World Report, Shanley led a survey of nearly 500 pharmacists and dermatologists across 128 categories to find the best over-the-counter products out there — with not a single brand paying to be on the list. In this episode, Wendy and Shanley cut through the “paralysis by analysis” and build your Healthy-Aging Shelf: the pro-approved picks for skin and hair, hormones and menopause, sleep, strength, and gut health in midlife. From CeraVe and La Roche-Posay to Estroven, Vital Proteins, Voltaren, and Metamucil, you'll walk away knowing exactly what to reach for. No hype, no guesswork. Just what works.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Most people see a global company and assume success happened overnight.What they don't see are the years of persistence, the skepticism, and the countless decisions required to turn a vision into reality.In this episode of Startup to Stock Exchange, Seth Farbman sits down with Leandro Iglesias, CEO of IQSTEL, and Alvaro Quintana, CFO of IQSTEL, to discuss how they transformed a telecom startup into a publicly traded global business operating across 30 countries.The conversation explores IQSTEL's journey from a $10 million revenue company to a business approaching a $500 million run rate, their path from the OTC markets to Nasdaq, and how they're evolving beyond telecom into AI, cybersecurity, fintech, and digital health services.Leandro and Alvaro also share their acquisition strategy, lessons from managing teams across multiple continents, and why they believe the company's biggest growth opportunities are still ahead.Whether you're a founder, investor, or business leader, this episode offers valuable insights into scaling internationally, leveraging public markets, and building a company with long-term vision.Guests featured in the episode:Leandro Jose Iglesias, CEO at IQSTEL : https://www.linkedin.com/in/leandro-jose-iglesias-20940818/Alvaro Quintana Cardona, CFO at IQSTEL: https://www.linkedin.com/in/alvaro-quintana-cardona-921494/IQSTEL: https://www.iqstel.com/Seth's CompaniesVstock Transfer – https://www.vstocktransfer.com/Share Media – https://www.sharemedia.co/Listen to the ShowApple Podcasts – https://podcasts.apple.com/us/podcast/seth-farbman-on-podcast-from-startup-to-stock-exchange/id1356667808Spotify – https://open.spotify.com/show/54i7xkWaAALAFrUvk4WZcNConnect with SethLinkedIn – https://www.linkedin.com/in/sethfarbman/Instagram – https://www.instagram.com/sethfarbmanstockTikTok – https://www.tiktok.com/@sethfarbmanTwitter (X) – https://x.com/sethfarbman1About the ShowFrom Startup to Stock Exchange, hosted by entrepreneur and investor Seth Farbman, spotlights the journey of founders and CEOs as they scale their companies from early ideas to public markets. Each episode features candid conversations with leaders across industries, offering insights on growth, fundraising, branding, and the mindset it takes to build a company that lasts.Chapters:00:00 Intro & Meet the IQSTEL Leadership Team01:55 How IQSTEL Started 18 Years Ago04:00 The Reality of Becoming a Public Company05:45 From Telecom Company to AI, Cybersecurity & Fintech09:00 Growing Revenue from $13M to $400M+11:40 How the CEO and CFO Built the Company Together14:40 Managing a Business Across 30 Countries18:00 The Acquisition That Could Push IQSTEL Past $500M24:15 Why Banks Said Their Vision Was Impossible28:15 Why IQSTEL Chose the Public Markets30:45 The Road to $1 Billion Revenue33:00 What's Next for IQSTEL and Its ShareholdersConnect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1

Mike McCormick from Florida's Poison Control Centers joins JMN to raise awareness to "The Benadryl Challenge." What is that, you ask? The “Benadryl Challenge” is a viral social-media trend that encourages young people to take dangerous amounts of the over-the-counter (OTC) drug diphenhydramine (DHP), that has led to the deaths of several young people. Mike shares ways to inform, educate, and promote safety against this and similar social media campaigns. If you have questions about this, other trending substances (Kratom, 7OH "Tranq," NO2 "Whippets", etc), or about the risks of opioid or OTC overdoses, or other concerns reach out to Florida's Poison Control Centers at 800-222-1222, or FLORIDAPOISONCONTROL.ORG .

Anhören, lachen, abstimmen! Von 1LIVE.

On this episode of The Still Real to Us Show:-- Sami Zayn Holds the Fate of the Undisputed WWE Championship in His Hands! Sami has been named the special guest referee for Cody Rhodes vs. Gunther on SmackDown, but can he remain impartial—or is controversy inevitable?-- "Come and Get Me!" Solo Sikoa Rejects Roman Reigns as Jacob Fatu Chooses a Side! Jacob Fatu delivers a direct message from Roman Reigns, Solo fires back with a challenge to the OTC, and Fatu officially joins The Bloodline. Is the next chapter of The Bloodline Civil War about to begin?-- Who Will Wear the Crown? King & Queen of the Ring and Owen Hart Tournament Predictions! Oba Femi's monster run continues, IYO SKY moves one step closer to the throne, Mercedes Moné punches her ticket to the Owen Hart Finals, and Will Ospreay vs. Swerve Strickland feels bigger than ever. We break down every tournament and predict who leaves with the crown and who leaves with the cup!-- Has TNA's Comeback Already Run Out of Steam? After a much-talked-about resurgence, TNA is dealing with talent departures, declining attendance, production cuts, and questions surrounding the WWE partnership. Is this just a rough patch—or are the warning signs impossible to ignore?

En Capital Intereconomía comenzamos la hora con el Radar Empresarial, donde analizamos el impacto económico de las falsificaciones en la industria deportiva. Un fenómeno que genera pérdidas multimillonarias para fabricantes y marcas de referencia, afecta a la innovación y supone uno de los principales desafíos para la protección de la propiedad intelectual a nivel global. En el Foro de la Inversión hablamos con Patricia Fitzgerald, fundadora de MentorWallet, para conocer en profundidad este nuevo proyecto orientado a ayudar a los inversores a tomar decisiones financieras más informadas y alineadas con sus objetivos patrimoniales. Durante la conversación repasamos la trayectoria profesional de su fundadora, el origen de MentorWallet y las necesidades que busca cubrir en un entorno donde el acceso a la información financiera es cada vez mayor, pero donde muchos ahorradores siguen necesitando orientación y acompañamiento para construir una estrategia de inversión sólida. También analizamos a qué perfil de inversor se dirige la plataforma y por qué considera que este es el momento adecuado para impulsar una iniciativa de estas características. La jornada se completa con Cripto Capital junto a Javier Pastor, Head of OTC de Bit2Me, para analizar el momento que atraviesa el mercado de los activos digitales. En Capital Intereconomía comenzamos la hora con el Radar Empresarial, donde analizamos el impacto económico de las falsificaciones en la industria deportiva. Un fenómeno que genera pérdidas multimillonarias para fabricantes y marcas de referencia, afecta a la innovación y supone uno de los principales desafíos para la protección de la propiedad intelectual a nivel global. En el Foro de la Inversión hablamos con Patricia Fitzgerald, fundadora de MentorWallet, para conocer en profundidad este nuevo proyecto orientado a ayudar a los inversores a tomar decisiones financieras más informadas y alineadas con sus objetivos patrimoniales. Durante la conversación repasamos la trayectoria profesional de su fundadora, el origen de MentorWallet y las necesidades que busca cubrir en un entorno donde el acceso a la información financiera es cada vez mayor, pero donde muchos ahorradores siguen necesitando orientación y acompañamiento para construir una estrategia de inversión sólida. También analizamos a qué perfil de inversor se dirige la plataforma y por qué considera que este es el momento adecuado para impulsar una iniciativa de estas características. La jornada se completa con Cripto Capital junto a Javier Pastor, Head of OTC de Bit2Me, para analizar el momento que atraviesa el mercado de los activos digitales. Repasamos las señales que apuntan a una expansión del ecosistema de Bitcoin y el creciente interés institucional por las criptomonedas. Además, ponemos el foco en uno de los grandes hitos regulatorios del año: la entrada en vigor, el próximo 1 de julio, de las nuevas normas europeas para el sector. Analizamos qué cambia realmente para los inversores, las plataformas y las empresas del ecosistema, y cómo afectará la nueva regulación al desarrollo del mercado cripto en Europa.

XRP may be entering a phase that most investors never saw coming. While the market remains focused on price, the infrastructure being built around XRP continues to expand at an incredible pace. Flare is unlocking new utility for XRP through smart contracts and DeFi. RLUSD is rapidly expanding across chains. Ripple is investing in global payment infrastructure. And new tools are making liquidity and interoperability more accessible than ever before. The question is no longer whether XRP has utility. The question is whether the market fully understands what XRP is becoming. Tonight, Jeff and Chip break down the latest developments from Ripple, Flare, RLUSD, Xaman, cross-chain interoperability, institutional adoption, and why these pieces may be combining into something much bigger than most people realize.

We break down migraines as a neurologic condition with a real brain-based chain reaction, not a character flaw or a one-off “bad headache.” We share practical prevention habits, how to track triggers, and how acute and preventive migraine medications fit together so you can walk into your next visit prepared. • what makes a migraine different from other headache types • common and less common migraine presentations including aura and scary look-alikes • the five-step migraine chain reaction including CGRP and pain amplification • high-yield triggers like stress, sleep changes, skipped meals, hormones, smells, and weather shifts • consistency as the core prevention theme across sleep, exercise, eating, and stress • migraine diary basics to identify patterns and improve your neurologist visit • when headaches warrant a call to a clinician and what red flags to take seriously • acute treatment options including OTC meds, triptans, CGRP blockers, and anti-nausea meds • medication overuse headache risk when acute meds are used too often • preventive options including beta blockers, anti-seizure meds, antidepressants, and Botox You can find us on Threads, you could send us an email, or you can send us some fan mail. We still have that voice-based fan mail still waiting for that first fateful one. Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Anhören, lachen, abstimmen! Von 1LIVE.

 In this special live episode recorded at the Country Music Hall of Fame in Nashville, Tennessee during the Sustainable Packaging Coalition Impact Event, Cory Connors shares the stage with Olga Kachook to present the Third Annual Sustainable Packaging Trends Report for 2025–2026. Olga walks through the four key trends shaping the industry and dives deeper into each one in conversation with Cory, covering everything from EPR maturity to innovation in healthcare packaging.Key Topics Discussed:Regions defining recyclability — Canada, the UK, and the EU leading the way and what that means for the USInnovation breakthroughs in OTC and healthcare packaging, including paper prescription bottlesEPR turning five — progress made and challenges that remainShared data driving recyclability clarity, including the upgrade of polypropylene cold cups under the How to Recycle programDesigning for EPR — setting your own certainty in the face of regulatory uncertaintyThe "magic wand" thought experiment: how would you design your packaging portfolio if starting fresh today?Coated paper and molded fiber as focus areas for the SPC's paper recyclability collaborativeThe role of AI sorting technology in generating better recycling dataReusable e-commerce as an emerging opportunity — FedEx and Returnity's B2B partnershipPredictions for the 2027 Trends Report, including consumer education and infrastructure expansion in EPR statesCabinet Health's refillable OTC packaging model, available at Target and AmazonResources Mentioned:Sustainable Packaging Coalition (SPC) SPC Paper Recyclability CollaborativeHow to Recycle ProgramCabinet Health — refillable OTC packagingNextGen ConsortiumReturnity Reusable ShippingContact: For more information on the SPC Trends Report, scan the QR code mentioned in the episode or visit sustainablepackaging.org.Thank you for tuning in to Sustainable Packaging with Cory Connors, presented by Atlantic Packaging!Support our Sponsors Learn more here:- 3M- Specright- Forest Connect with CoryConnect with Cory on LinkedIn here: https://www.linkedin.com/in/cory-connors/I'm here to help you make your packaging more sustainable! Reach out today and I'll get back to you asap. This podcast is an independent production and the podcast production is an original work of the author. All rights of ownership and reproduction are retained—copyright 2022.

Is El Salvador truly a Bitcoin paradise, or are banks winning the war? AsoBitcoin President Will Hernandez (@whbitcoin) reveals the truth about banking, taxes, and real estate.If El Salvador is the ultimate haven for financial freedom, why is it still an absolute nightmare for a Bitcoin company to open a simple savings account? There is a massive disconnect between political idealism and reality on the ground even though several years have passed since the historic bitcoin law entered into force. In this episode, Will Hernandez, President of the El Salvador Bitcoin Association (AsoBitcoin), joins us in the studio to pull back the curtain on what it actually takes to operate a business inside the first country to make Bitcoin an official legal tender.We tackle the legacy financial system because it represents the biggest battleground for business owners right now. Traditional Salvadoran banks are actively utilizing their legal right of refusal to lock out crypto startups, which proves that institutional hostility remains a major hurdle. To bypass this friction, we lay out a major three month challenge for the association to develop a sovereign tax framework alongside the government. If businesses can pay their corporate and payroll taxes entirely in Bitcoin via OTC intermediaries, entrepreneurs can finally opt out of the fiat system and achieve true corporate asset protection.International capital continues to flood into the country due to unprecedented corporate tax incentives. Will explains how international founders are completely restructuring their corporate balance sheets because El Salvador charges zero percent capital gains tax when you hold a digital asset in your corporate treasury. This unique tax exemption has triggered a massive boom in the local property market, and it has transformed the coastline into a global hotspot for real estate investment where buyers use specialized OTC desks to close deals entirely on a bitcoin standard.The grassroots movement is winning the long game through localized Bitcoin circular economies while legacy institutions stall. From surf towns like El Zonte to new tech hubs, communities are building a parallel economy where everyday users constantly refine the software UX. Will emphasizes that the next critical step involves structural education, and he is pushing the Ministry of Education to mandate Bitcoin literacy in private school curriculums so that the next generation natively understands sound money systems.El Salvador is already positioning itself for the next technological super-cycle by exploring the intersection of decentralized money and sovereign AI. The government is actively pushing its own officials to adopt these emerging technologies because it anticipates a future where autonomous AI agents use the Bitcoin network for automated machine-to-machine payments. This episode provides an unfiltered, boots-on-the-ground look at the triumphs, structural bottlenecks, and future of the ultimate macroeconomic experiment.If you enjoyed this episode and want to keep supporting open source freedom money, please make sure to subscribe to the channel, share this with a fellow Bitcoiner, and drop a comment below. Just let us know if you think Will can pull off the tax challenge in three months or if Mike needs to call him out on the next show.—Bitcoin Beach TeamLearn more about Will Hernandez:X: https://x.com/whbitcoinIG: https://www.instagram.com/whbitcoin/LinkedIn: https://www.linkedin.com/in/whbitcoin/Web: https://www.asobitcoin.org/Support and follow Bitcoin Beach:X: https://www.twitter.com/BitcoinBeach IG: https://www.instagram.com/bitcoinbeach_sv TikTok: https://www.tiktok.com/@livefrombitcoinbeach Web: https://www.bitcoinbeach.com Browse through this quick guide to learn more about the episode:00:00  Intro01:48  Will Hernandez: The famous 3 BTC birthday piñata story03:37  Why Bitcoin entrepreneurs must study the Satoshi white paper06:36  How AsoBitcoin filters out crypto scams in El Salvador09:31  Is the El Salvador Bitcoin Association private or government?13:28  Why do traditional banks in El Salvador reject Bitcoin startups?15:05  What is the El Salvador Law of Alternative Funds?17:26  How to buy real estate in El Salvador using Bitcoin and OTC desks24:34  How to pay corporate taxes on a pure Bitcoin standard28:58  Pushing for a mandatory Bitcoin curriculum in private schools36:09  Sovereign AI: How autonomous agents use Bitcoin for paymentsLive From Bitcoin Beach

**THEY JUST REVEALED XRP'S ENDGAME** Most people still think XRP is about payments. But this week, Ripple revealed a much bigger picture. From AI agents transacting autonomously with XRP and RLUSD, to enterprise stablecoin settlement, quantum readiness, and the continued expansion of the XRP Ledger ecosystem, the pieces are starting to fit together. While much of the crypto market remains focused on price action, Ripple appears to be building infrastructure for a future where machines, businesses, and financial institutions exchange value at internet scale. In this episode, we break down Ripple's new XRPL AI Starter Kit, the launch of Bitso's MXNB stablecoin on XRPL, Fortune's recognition of XRP among the most influential blockchain projects, Ripple's multi-phase approach to quantum security, and Hugo Philion's comments on why the entire industry now seems to be chasing the very role XRP was originally designed to play. If these developments are connected, then XRP's endgame may be far bigger than most people realize.

Semaglutide Slows Biological Aging A randomized, placebo-controlled study published in Nature Communications found semaglutide slowed biological aging markers by nine percent on the DunedinPACE epigenetic clock in adults living with HIV-associated metabolic disease, with simultaneous improvements across inflammation, heart, kidney, liver, and brain markers. Host Dave Asprey breaks down why this isn't a weight loss story. It's a metabolic inflammation story. He explains why the GLP-1 mechanism hitting insulin signaling, oxidative stress, and inflammatory pathways simultaneously is the real finding, and makes the case that your metabolic markers and your aging markers are the same numbers. Sources: https://www.medicalnewstoday.com/articles/glp-1-drugs-ozempic-wegovy-may-slow-biological-aging https://www.nature.com/articles/s41467-026-72861-3 https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging FDA Approves First New Sunscreen Ingredient in 20 Years The FDA approved bemotrizinol as a permitted OTC sunscreen active ingredient, the first new approval in roughly two decades, clearing it for adults and children six months and older with broad UVA and UVB coverage and low skin absorption. Host Dave Asprey explains why twenty years of regulatory lag left American consumers with inferior chemistry while Europe moved on, why he's watching independent absorption data before updating his own stack, and why consistency of use matters more than perfect formulation when sun protection remains one of the most evidence-backed longevity interventions available. Sources: https://www.fda.gov/news-events/fda-newsroom/press-announcements/fda-expands-sunscreen-options-first-time-20-years https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=OrderDetail&orderid=OTC000039 https://www.usatoday.com/story/news/health/2026/06/09/new-sunscreen-ingredient-bemotrizinol/90477659007/ Deoxyribose Gel Matches Minoxidil in Hair Regrowth Study Researchers testing a topical gel made from deoxyribose, the sugar backbone of DNA, saw roughly 80 to 90 percent hair regrowth in a mouse model of male-pattern baldness, matching minoxidil results and showing new follicle formation and increased blood vessel activity in treated areas. Host Dave Asprey breaks down why mouse hair regrowth studies have a long history of failing to translate to humans, what a plausible circulation-based mechanism would actually need to show in human trial data before it's worth acting on, and why the molecule itself is interesting enough to keep watching. Sources: https://www.reddit.com/r/Biohackers/comments/1tyt87w/researchers_found_that_a_gel_made_from/ https://www.sciencealert.com/surprise-hair-loss-breakthrough-a-dna-sugar-gel-sparks-robust-regrowth Caffeinated Chewing Gum and Exercise Performance A systematic review and meta-analysis of 21 studies found caffeinated chewing gum produces a small but real ergogenic effect for muscular strength and countermovement jump height, with buccal absorption delivering caffeine faster than capsules or drinks in a five to twenty-five minute pre-training window. Host Dave Asprey breaks down why delivery mechanism is an underrated variable in caffeine optimization, why timing matters as much as dose, and why a modest but measurable edge on a cheap and accessible tool is exactly the kind of practical biohack worth understanding. Sources: https://pubmed.ncbi.nlm.nih.gov/42228847/ https://doi.org/10.1519/JSC.0000000000005530 https://www.reddit.com/r/Biohackers/comments/1u0acgc/fastacting_caffeine_does_caffeinated_chewing_gum/ Vitamin A Overdoses Surge Nearly 40 Percent Medical News Today reported a 38.7 percent spike in vitamin A overdoses in early 2025, driven by online misinformation claiming high-dose vitamin A treats or prevents measles, a claim with no clinical support and real toxicity risk from fat-soluble accumulation in the liver. Host Dave Asprey explains the actual hepatotoxicity and bone demineralization risks of preformed retinol excess, draws the critical distinction between preformed retinol and beta-carotene that got lost in the misinformation cycle, and makes the case that mechanism is not a dosing protocol and confusing the two is how people get hurt. Sources: https://www.medicalnewstoday.com/amp/articles/vitamin-a-overdoses-rose-by-38-7-2025-how-to-get-right-amount World Cup 2026 and Mass Gathering Health Risk With the 2026 FIFA World Cup underway, public health researchers are flagging dense international crowds, high-volume travel, and shared indoor and outdoor spaces as an elevated transmission environment for respiratory illness. Host Dave Asprey reframes the conversation away from germ exposure and toward immune terrain, explains why your resilience going into a high-contact environment is a variable you actually control, and lays out the pre-exposure preparation window that matters most for anyone traveling or attending large events this summer. Sources: https://www.healthline.com/health-news/2026-fifa-world-cup-health-risks-protect-yourself This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on GLP-1 aging biology, sunscreen chemistry and regulatory science, emerging hair regrowth research, caffeine delivery optimization, supplement toxicity risk, and immune terrain preparation for mass gathering events. Host Dave Asprey connects randomized clinical data, epigenetic clock research, consumer health regulation, and real-world optimization protocols into actionable frameworks for extending healthspan, sharpening performance, and staying ahead of the science. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: semaglutide biological aging, GLP-1 epigenetic clock, DunedinPACE aging marker, PCGrimAge mortality risk, bemotrizinol FDA approval, new sunscreen ingredient 2026, UVA UVB broad spectrum sunscreen, deoxyribose hair gel, minoxidil alternative hair regrowth, caffeinated chewing gum performance, buccal caffeine absorption, pre-workout caffeine timing, vitamin A overdose toxicity, preformed retinol hypervitaminosis, fat-soluble vitamin accumulation, World Cup 2026 health risk, immune terrain optimization, mass gathering respiratory illness, biohacking news 2026, longevity research, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Viome | Check it out at viome.com and use code 10DAVE for 10% off. It's time to stop guessing and start knowing your body. - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:41 – Story 1: Ozempic Slows Aging Clocks 01:53 – Story 2: New Sunscreen Approved 03:12 – Story 3: DNA Sugar & Hair Regrowth 04:38 – Story 4: Caffeine Gum & Performance 06:13 – Story 5: Vitamin A Overdose Spike 07:59 – Story 6: World Cup & Immune Prep 09:34 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For years, XRP holders have been told the story was about payments. But after this week's announcements from Ripple, XRPL, RLUSD, Mastercard, and the growing push toward autonomous AI transactions, a much bigger question is beginning to emerge. What if payments were never the destination? Tonight, we connect the dots between Ripple's new XRPL AI Starter Kit, Mastercard's Agent Pay initiative, RLUSD, AI agents, machine-to-machine commerce, XRP perpetuals on Kalshi, Flare's growing role in decentralized data infrastructure, and why Tom Lee believes AI actually increases the need for blockchain. We'll also discuss the latest developments surrounding the Clarity Act, Ripple's expansion into Asia, formal verification efforts on the XRP Ledger, and the biggest stories shaping crypto, markets, and geopolitics. The more pieces that emerge, the harder it becomes to ignore one possibility: This may be why XRP exists.

Didier Deschamps' titans enter this year's World Cup as the team to beat. Champions in 2018 and runners-up in 2022, Les Bleus are the favourites in North America. But can they reclaim this most coveted crown?Andy is joined by OTC regular Jonathan Johnson to dissect France's star-studded squad. Is Kylian Mbappé's influence helpful - or harmful? How do Michael Olise, Ousmane Dembélé and Désiré Doué fit into a stacked front line? What will be sacrificed for glory?Ask us a question on X, Instagram and TikTok, and email us here: otc@footballramble.com.For ad-free shows, head over to our Patreon and subscribe: patreon.com/footballramble.***Please take the time to rate and review us on Apple Podcasts or wherever you get your pods. It means a great deal to the show and will make it easier for other potential listeners to find us. Thanks!*** On The Continent is your definitive podcast for European football. Subscribe for new podcasts every single week and throughout the 2026 FIFA World Cup. Hosted on Acast. See acast.com/privacy for more information.

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics for living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Title: Digestive Enzymes, Gut Health, and Omega-3's with Guest Brenda Watson [0:00:00] Show Intro,  National Club Foot Day & Prior Episode Reference Ed mentions National Club Foot Day (previous Wednesday). References a prior Vital Health Radio episode where he strongly criticized a local Chattanooga physician for poor club foot care that nearly harmed his grandson. Ed urges: Anyone with a child/grandchild with club foot seeing providers in Chattanooga  listen to our Feb 15th (2026) episode Contact: NutritionWorld@comcast.net to get details of that show and the physician referenced. Emphasis on truth, empowerment, and avoiding harm from medical “inefficiency and ignorance.” [0:03:58] Delta-8 Gummies, Anxiety/Sleep & Lifespan Extension Concepts Recap of a recent show with Hemp House. Ed explains: Only about three weeks left to legally purchase Delta-8 gummies at Hemp House or Nutrition World. Why someone might use Delta-8: Anxiety Trouble sleeping Need to stay functional but calmer Must find the right dose individually (no standard dosing). Safer than many anti-anxiety drugs when used properly. He is saving several containers in his freezer for future “bumps in the road” (periods of poor sleep or high stress). Notes dogs may benefit for anxiety, thunder phobia, pain, etc., when used correctly and from a trusted company. Ed recommends Dr. David Sinclair's “Lifespan” podcast: Focus on practical drugs, supplements, and lifestyle strategies to extend lifespan. Central concept: cellular repair – if we repaired cells at 50 as well as at 20, lifespan could drastically increase. Key tools Dr. Sinclair highlights (as relayed by Ed): Rapamycin – Ed takes this drug himself; impacts mTOR; can extend lifespan even when started later in life. AMPK activators – sold at Nutrition World; support clearing out old/dysfunctional cells. Resveratrol – mimics some effects of fasting. Hyperbaric oxygen – discussed as a potential lifespan extender. Ed shares Sinclair's animal-longevity illustrations: A mole rat living ~20x longer than regular rats → proves there are mechanisms of extended lifespan. A long-lived whale (Clint jokes and riffs on the name) said to reach ~200 years, suggesting humans might mimic similar mechanisms. [0:08:46] Call for Listener Stories & Introduction of Guest Brenda Watson Ed invites listeners to share personal health recovery stories, especially involving “the Green Pharmacy” (natural, nutritional, and lifestyle approaches, including Nutrition World support). Announced collaboration with Clint Powell on a new podcast: Short, credible motivational/educational stories (5–20 minutes). Focus: “I was in bad shape, now I'm much better” recovery narratives. Participants receive a $50 Nutrition World gift card. Recordings at a studio ~5 minutes from Nutrition World. Introduction of guest Brenda Watson, founder of Vital Planet. Described as a guru of gut health and the microbiome: Leaky gut, SIBO, broad digestive health expertise. Ed recalls her long-running NPR fund-raiser specials on gut health that reached tens of thousands. [0:13:25] Digestive Enzymes, Gut Health & Problems with Acid Blockers Topic: What is an enzyme? Why does it matter? Brenda's explanation: Enzymes “break things apart”: Protease → breaks proteins into amino acids. Amylase → breaks starches into glucose. Lipase → breaks fats into fatty acids. Ideally, stomach, pancreas, liver, and gallbladder work together to digest food into absorbable units. Early digestive symptoms: Heartburn, gas, bloating, etc. Many people self-treat with OTC antacids or proton pump inhibitors (PPIs) and this often worsens underlying issues. Her main point: For early digestive symptoms, start with a full-spectrum digestive enzyme (protease, amylase, lipase) with meals, not acid-blocking drugs. As we age, natural digestion weakens, compounded by poor food quality. If food is not properly digested: It rots in the gut → gas, overgrowth of “bad bugs”. Contributes to SIBO, leaky gut, and broader dysbiosis. Leads to poor absorption of nutrients and worsening health. Enzymes as Step One: Should be a first-line intervention alongside or even before probiotics. Emphasizes that digestive enzymes for digestion must be taken with meals. Brenda notes she ran a stool test program with 12 people; often saw imbalanced gut bacteria driven by undigested food. Modern enzyme formulations can be more targeted: Gluten-support enzymes. General high-potency formulas. Formulas for dairy and fat, especially for people on keto who need extra fat-digesting support. She reiterates: Poor digestion = bad bacteria, leaky gut, SIBO, multiple gut issues. Digestive enzymes are a “no-brainer” first step when digestive symptoms appear. [0:23:47] Enzymes as a Foundational Strategy & Aging, Pancreas/Bile Physiology Emphasizes: Rotting food analogy: leftover food in a trash can on a 97°F day = what undigested food can be like inside the gut. Even without symptoms, after age ~40–45, enzymes may be wise especially for people who: Overeat Eat a lot of dairy or gluten Notes loose stools and general poor health can be caused by lack of pancreatic enzymes. Shares a case where a client's stool test showed zero pancreatic enzyme production, correlating with constant sickness. You can “get away with” some other health issues, but you cannot have a dysfunctional digestive tract and still expect even average health. Brenda further explains physiology and pH: Stomach should be very acidic (pH ~2) during digestion. When partly digested food moves into the small intestine: Bicarbonate is released to neutralize acid. Pancreas releases enzymes (protease, amylase, lipase). Liver/gallbladder release bile for fat digestion near the same region. If stomach acid is suppressed, the chain reaction is disrupted: Poor enzyme activation. Poor bile function. pH shifts can foster candida and other imbalances (e.g., colon getting too alkaline). She underscores: From mouth to colon, each region needs appropriate pH. Chronic use of acid blockers has long-term downstream consequences. Ed mentions a simple at-home baking soda test to roughly gauge stomach acid (baking soda in water between meals, watching for burping). Important caution: If you're on acid-blocking medications, you must wean off slowly; do not stop abruptly. Nutrition World's pharmacist, Dr. Curt Dearing, helps people step down from PPIs and H2 blockers safely (in partnership with their physicians). [0:30:58] Omega-3s , Purity, and Heart/Brain Health Ed highlights Vital Omega (Vital Planet): #1 selling product at Nutrition World. Exceptional purity and transparency (heavy emphasis on contaminant-free sourcing). Very high potency (2350 mg of EPA/DHA per serving). No “fish burp” complaints and virtually no returns. Contains lipase enzyme to support fat digestion and further reduce digestive discomfort. Omega blood tests on customers show high omega-3 levels when using this brand. Brenda agrees: Omega-3s are critical at any age, especially in today's toxic environment. You might skip a multivitamin, but you should not skip omega-3s. Ed's additional points: Olive oil and flax oil are not the same as concentrated EPA/DHA. EPA/DHA are essential for cell membranes, cardiovascular health, and cognitive function. Warns of contaminated fish oil from polluted waters (mercury, heavy metals, etc.). Website plug for Vital Planet: VitalPlanet.com for education, and product details. Ed reiterates his respect for Brenda's decades of ethical, passionate work and says they'll have her back on again.   [0:38:54] Lifestyle, Local Food, Pillows, and Environmental Toxins Ed and Clint return; Ed summarizes the show's philosophy: Better aging is about strength, clarity, mobility, energy, not just added years. Introduces term “peak span”, maximizing the years we're at peak function, not just lifespan. Critiques normalization of poor health (hunched posture, chronic pain, poor sleep, anxiety) as “just getting old.” Local food talk: Discussion of Tallow House in Cleveland (burger restaurant, cousin of Tony from Portofino). Two-hour waits, excellent reviews, smash burgers, buns from Neidlovs bakery. Dust mites and pillows: Ed cites data that about 1/3 of a pillow can be dead skin + dust mites over time. Many pillows also contain fire retardant chemicals leading to chronic exposure while sleeping. Ed searched for non-toxic pillows via Mamavation: A site that tests products for chemical residues and rates them. His previous pillow (from Avocado) came out top-rated, so he bought a new Avocado pillow. Recommends buying via Mammovation's affiliate link for a small discount. [0:44:00] Essential Oils, Green Pharmacy & Polypharmacy Ed on essential oils quality: A test of 20 lavender oils from Amazon found: Only 3 were pure. 17 were diluted/contaminated with other oils. Smell alone isn't a reliable indicator of quality. Nutrition World only carries brands with Certificates of Analysis; dropped an entire line a few years back over quality concerns. Ed shares a Taiwanese blood pressure study: 58 adults with high blood pressure, many on meds. wore a face mask with a cotton pad containing small amounts of real lavender oil for 15 minutes/day over 7 days. Result: systolic blood pressure reduced by ~10 points. A placebo (fake) oil did not reduce blood pressure. One-day use showed no benefit – consistent use was required. He frames this as an example of the “Green Pharmacy”: Mentions Dr. Curt Dearing (pharmacist at Nutrition World): Helps people review and rationalize medication lists, with the goal of reducing polypharmacy in collaboration with prescribing doctors. References a recent Vital Health Radio episode on polypharmacy (average American takes ~17 prescriptions per year). [0:56:48] Meditation, Mindset, Ancient Wisdom & Fulfillment Story from the Daily Stoic: Kurt Vonnegut and Joseph Heller at a billionaire's party: Vonnegut points out the host made more money yesterday than Heller's Catch-22 ever did. Heller replies he has something the billionaire never will: “the knowledge that I've got enough.” Ed uses this to emphasize: The power of knowing you have enough. Shifting from chasing money to working for fulfillment once basics are covered. Clint adds: You must learn to be content with what you have while still pursuing goals. More stuff doesn't automatically create a content person. Ed reads a longer reflection on “ancient wisdom” vs. modern medicine: Fundamental philosophy: alignment with nature. Humans thrived for millennia without pharmaceuticals (acknowledges infectious disease issues before hygiene and antibiotics). Nearly every drug has unintended consequences and rarely treats root causes. Cites estimate: medical errors as the 3rd leading cause of death in the US (~250,000 deaths/year). Notes ~90% of American calories now come from processed foods and seed oils Argues seed oils are among the most destructive components of the modern diet. Many cardiologists still recommend them as heart-healthy, highlighting the conflict between mainstream and holistic views. Plug for Ed's book: “Are You Sick and Tired of Being Sick and Tired” available at TheHolisticNavigator.com, built around ancient wisdom.  The post Radio Show / Podcast – June 7, 2026 first appeared on Vital Health Radio.

Jeff and Zack have the opportunity to sit down and chat with Washington State Department of Fish and Wildlife Ungulate Section Manager Kyle Garrison and Ungulate Specialist William Moore to get a debrief on all things Washington Ungulates, herd numbers, and chat about the OTC vs Draw Only system changes that could be proposed in the next few years. We are very thankful to them for stepping out on a branch to do this podcast and hope it is just the first of many to come so we can begin to have more transparency between the department and the hunting public of this state.  LINKS: KUIU GEAR - https://kuiu.sjv.io/GK1o7m EXO MOUNTAIN GEAR - https://exomtngear.com?ref=4 VORTEX OPTICS - https://alnk.to/cSJYlok MARSUPIAL GEAR - https://alnk.to/5FcU7YA ZOLEO - https://tinyurl.com/428ydbua PNWILD - https://www.pnwild.com/store-snytH DEVOS OUTDOOR LIGHTING - https://rstr.co/devosoutdoor/15643 COUPON CODES: OLLIN DIGISCOPE - PNWILD CANYON COOLERS - PNWILD10 VORTEX CLOTHING - PNW20 ZOLEO SATELLITE - PNWILD (Free Activation) VELOTRIC E-BIKES - PNWildN2X01 PNWILD - YOUTUBE If you want to learn more about PNWild visit https://pnwild.com/ INSTAGRAM: @pnwild_ https://www.instagram.com/pnwild_/?hl=en FACEBOOK: / pnwild TIKTOK: @pnwild_ / pnwild_ Got questions? Send us an email! Email: contact@pnwild.com Find all PNWild Partners and Codes here: https://www.pnwild.com/partners

Anhören, lachen, abstimmen! Von 1LIVE.

Matt and Nic are back for another week of news and deals. In this episode:  FIFA's World Cup ticketing scandal Andrew Yang is now a crypto and telecoms entrepreneur Are Strategy's woes responsible for the Bitcoin pullback? Will Saylor defend STRC or MSTR? What are Saylor's options here? Polymarket has another market resolution SNAFU How UMA could be used to exploit Polymarket BitMine considers a perpetual preferred security Google's quantum circuit is optimized by hobbyists Galaxy launches OTC trading for prediction markets Treasury sanctions Iran's largest digital asset exchanges Andrew Left of Citron research is convicted of securities fraud

You may think of allergies as causing sniffly noses and congestion in the spring or fall. But allergies can go far beyond that. As Dr. Kari Nadeau points out in this episode, allergies can affect us from head to toe, including eyes, nose, throat, lungs, sinuses, skin and gut. In the most dangerous instances, the whole body is threatened with an anaphylactic reaction. That's a medical emergency! One in three Americans will develop allergies at some point in our lives, so it's important to know what works to control them. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, June 6, 2026, through your computer or smart phone (wunc.org).  Here is a link so you can find which stations carry our broadcast. (Welcome, Huntsville, Alabama!) If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on June 8, 2026. What Are Allergies? We begin our discussion of your allergy survival guide with an explanation of what is happening during an allergic reaction. The immune system perceives some foreign compound, usually a protein, as dangerous even though normally it would not be. So it reacts by trying to flush the invader out by producing extra mucus. The turbinate sinuses can make one to two gallons of mucus a day, and naturally, it has to go somewhere. That's why you might be congested. Having all that mucus in the sinuses can also encourage bacterial growth, so if the allergic reaction persists, some people have to deal with sinus infections. Emergency Treatment In determining what works, you need to know the nature of the reaction. If you have two or more organs involved, if you are having trouble breathing or if you feel dizzy, you may be in the midst of an anaphylactic reaction. What works for that is an epinephrine injection and immediate medical attention. This is potentially life-threatening, so you will want to figure out what triggered the reaction so you can avoid it in the future. Once someone has suffered one anaphylactic reaction, they should keep epinephrine with them at all times in case of another episode. Epinephrine comes as a self-injector pen or a nasal spray (neffy). Can You Spot Drug Allergies? In the warnings that are rattled off as part of a TV ad for a pricey new drug, we often hear viewers cautioned not to take the medicine if they are allergic to it. That sounds like simple common sense, but it also has a Catch 22 quality. How do you know you are allergic to a medication unless you take it–and experience an allergic reaction for which you might need treatment. Most of these presumably are immune system-mediated reactions, in which the body produces IgE. That is how allergies to penicillin or sulfa drugs work. Some drugs cause a different type of reaction, not IgE-mediated but dangerous nonetheless. Lisinopril is the most commonly prescribed blood pressure medicine in this country. Like other ACE (ACE is short for angiotensin-converting enzyme) inhibitor medications, lisinopril can trigger angioedema. This swelling can affect the face, lips, tongue and throat, where it can compromise breathing. The most insidious aspect of this reaction is that it can occur after the person has been taking the drug without problems for weeks, months or even years. “Red man syndrome” or infusion reactions in people taking vancomycin can likewise occur without warning. The last type of drug reaction is not actually an allergy at all, although people occasionally use that terminology. It is better described as sensitivity. For example, a stomachache is a common reaction to the antibiotic erythromycin. Some people are disabled by this abdominal pain and try to limit their exposure to erythromycin thereafter. What Works and What Doesn't? Since the immune system is acting inappropriately to cause allergic reactions, treatment should involve immunotherapy. Eye drops can help eyes feel less itchy and irritated. Likewise, OTC nose drops or nasal sprays can often help the nose. The corticosteroid Flonase (fluticasone) and the antihistamine Astepro (azelastine) are good examples. During allergy season, some people find that a daily nasal wash (with a neti pot or NeilMed device) can help reduce the mucus and remove the allergens such as pollen causing the reaction. There are also oral antihistamines and inhalers for asthma. For decades now, allergists have offered their patients shots to help desensitize them to the allergen causing their trouble. Joe had these as a child and teenager and has been largely free of allergies since. Not everyone gets such lasting relief. Complications from Current Therapies Medications have side effects, and that is true of allergy medicines as with other drugs. Antihistamines, especially the older ones like Benadryl (diphenhydramine), are notorious for causing drowsiness. That's one reason it is often included in nighttime pain relievers as the “PM” in drugs like Advil PM. We worry about regular use of such antihistamines because it has been linked to a greater risk for dementia. A second-generation antihistamine such as Allegra (fexofenadine) is much less likely to make someone feel sleepy. However, Dr. Nadeau has seen patients on antihistamines suffer worse allergies if they stop suddenly. The People's Pharmacy has received hundreds of reports from people who experienced unbearable itching upon discontinuing Zyrtec (cetirizine) or Xyzal (levocetirizine). This can last for weeks. Doctors don't usually worry much about steroid nasal sprays like Flonase because they are topical. Presumably, nasal tissues pick up most of the dose. Just the same, using such a nose spray day after day for a long time could result in systemic steroid exposure that is not trivial. Stronger Medicine Dr. Nadeau is enthusiastic about the benefits of two potent prescription medicines. One is Xolair (omalizumab). It was originally developed to prevent asthma, but is now approved for chronic sinusitis, food allergies and chronic hives. Paradoxically, Xolair is one of those medicines that could cause a severe allergic reaction even on the first dose, so the FDA warns that the initial injection should be given in a healthcare setting prepared to treat anaphylaxis. This is uncommon, though, occurring in 0.1 to 0.2% of patients. The other medication Dr. Nadeau is prescribing for allergy patients who don't respond well to other treatments is Dupixent (dupilumab). The FDA has approved this medicine to treat a wide range of conditions, including eczema, asthma, chronic sinusitis, allergic reactions affecting the esophagus and chronic hives, among other things. Most insurance companies will not cover this pricey injection unless the patient has failed all other therapies. Fighting Air Pollution: What Works Air pollution makes allergy symptoms worse, so using an effective air filter inside the home is a good step. A HEPA (high-efficiency particulate-arresting) filter is ideal, especially as part of the air-handling system. If that's not possible, utilizing a MERV 13 in the part of the home where you spend the most time is a good second choice. Sonu One new option for treating allergies is acoustic resonance therapy with the SoundHealth Sonu headband. It uses vibration from sound to loosen mucus from the sinuses so that they can clear. The FDA has approved its use for children as well as adults. New research was just published demonstrating its helpfulness in treating children with nasal congestion (Oto-Open, April-June 2026). SoundHealth has underwritten The People's Pharmacy podcast. Dr. Nadeau has also been compensated for her role in conducting studies of this device (International Forum of Allergy & Rhinology, Dec. 2025). Since it does not employ medications, there are no drug side effects. This Week’s Guest Kari C. Nadeau, M.D., Ph.D., is Dean of the UCLA Fielding School of Public Health ( starting July 1 2026). Until then, she holds many other positions. At Harvard T. H. Chan School of Public Health she is: John Rock Professor of Climate and Population Studies; Chair of the Department of Environmental Health; and Director of the Allergy, Extreme Weather, and Exposomics Lab. Dr. Nadeau is Professor of Medicine at Harvard Medical School and serves in the Division of Allergy and Inflammation at Beth Israel Deaconess Medical Center. She is an Adjunct Professor at Stanford Medical School. Dr. Nadeau is also the co-author of The End of Food Allergy, which provides strategies for treating and preventing food allergies in children. Here is a link to the research underway in her Harvard laboratory. PHOTO CREDIT: STACY GEIKENTaken in April 2017 at Kari Nadeau’s professorship dinner The End of Food Allergy: The Science-Based Plan That Turns Food into Medicine The People's Pharmacy is reader supported. When you buy through links in this post, we may earn a small affiliate commission (at no cost to you). Listen to the Podcast The podcast of this program will be available Monday, June 8, 2026, after broadcast on June 6. You can stream the show from this site and download the podcast for free. This episode has additional information about Nasalcrom (cromolyn sodium nasal spray) and its effect on mast cells; alpha gal allergy to red meat; and the latest thinking on preventing peanut allergy among young children. Download the mp3

0:00 – Ludwig Kaiser before Ludwig Kaiser10:45 – Roman discussion22:30 – Roman discussion33:15 – Roman discussion45:10 – Roman discussion55:50 – Roman discussion1:05:30 – Roman discussion1:16:15 – Roman Reigns and the boring Bloodline discussion1:22:45 – Show endBecome a supporter of this podcast: https://www.spreaker.com/podcast/wrestling-soup--1425249/support.

It was a pleasure to host a discussion with Ronnie Wexler, Global Head of Equities Distribution at Barclays, and solicit his insights on change – in markets, in client relationships and in the growing role of technology across the financial ecosystem. We begin with Ronnie's early years at Goldman Sachs during the final stages of the technology bubble and the sharp market reversal that followed. He reflects on how periods of market stress, from the post-dot-com bear market to the GFC, have shaped his perspective on risk and the importance of being adaptable in markets that are constantly moving. The conversation then turns to the changing structure of institutional investing. Ronnie discusses the growth of hedge funds in pursuit of industrial-scale alpha generation, highlighting how client needs have become increasingly cross-asset, and solutions-oriented. He explains how a sell-side equities business today functions as an integrated ecosystem that spans prime brokerage, derivatives, electronic trading, and financing. A major theme throughout the discussion is the accelerating pace of technological change. Ronnie describes recent experiences using AI development tools and outlines how firms are integrating them into workflows ranging from onboarding and automation to research distribution and client analytics. We also explore the rise of bespoke and OTC solutions, including quantitative investment strategies, custom baskets, and exotic option structures. Here Ronnie emphasizes that these products reflect broader changes in market structure, positioning, and risk transfer across institutional portfolios. The conversation concludes with thoughts on recruiting, apprenticeship culture, and the need for firms to balance human judgment with increasingly sophisticated technological infrastructure.

¡WWE RAW nos dejó mucho de qué hablar desde Turín, Italia! Luego de los acontecimientos en Clash in Italy, Roman Reigns celebró su victoria en Tribal Combat y finalmente Jacob Fatu reconoció al OTC como su Tribal Chief, uniéndose oficialmente al Bloodline en uno de los momentos más importantes de la noche.Además, comenzó el esperado torneo King & Queen of the Ring rumbo a SummerSlam. Oba Femi logró avanzar en el torneo King of the Ring tras imponerse en una intensa Fatal 4-Way sobre Penta, Solo Sikoa y Carmelo Hayes. Por el lado femenino, IYO SKY consiguió su boleto a la siguiente ronda del Queen of the Ring al derrotar a Roxanne Perez, Giulia y Lash Legend.También vimos a Rey Mysterio y Dragon Lee derrotar a Ethan Page y Rusev, mientras Sol Ruca celebró su reciente conquista del Campeonato Intercontinental Femenino. En el evento estelar, Seth Rollins consiguió una importante victoria sobre Bron Breakker en otro gran combate para cerrar la noche.Analizamos todos los resultados, las mejores luchas, el futuro del Bloodline, el arranque de King & Queen of the Ring y todo lo que dejó WWE RAW.¡Suscríbete a 100% Wrestling Podcast para más reviews, noticias, análisis y cobertura completa del mundo de la lucha libre!#WWE #WWERaw #RomanReigns

Atomic Eagle CEO Phil Hoskins stated: “Our 2026 goal of increasing Muntanga's Mineral Resource is off to a great start. These initial results from Chisebuka build directly on the Company's early success, which saw a 9.7Mlb uranium resource defined at Chisebuka in a matter of months. Chisebuka's SW zone is now emerging as the next key addition with near-surface higher-grade results outside of the previous resource area and we've only scratched the surface of the planned holes into Chisebuka this year. Drilling is continuing with two rigs aiming to expand the higher-grade zones at Chisebuka whilst at the same time, we are conducting ground radiometric surveys to refine the exciting Namakande and Muntanga North targets.” Hoskins says the company has grown the resource 24% from 47M lbs to 58M lbs and is running a major 30,000-meter drill program, with early Chisebuka holes largely hitting expected mineralization and potential for meaningful satellite resource growth. He outlines larger exploration upside at Muntanga North and Namakande using layered datasets including airborne and ground radiometrics, radon-in-soils, favorable host rocks, and structural targeting. Hoskins discusses expectations for consistent heap-leach metallurgy, progress toward environmental and resettlement approvals, infrastructure advantages, a low-cost option to acquire the Sitwi uranium project, recent board changes, ongoing Niger discussions on Madaouela as option value, and an OTC move from QB to QX. 00:00 Intro 00:26 Project Update Overview 01:21 Chisebuka Drilling Results 03:10 Next Big Targets 03:46 Targeting Methodology 05:07 Metallurgy and Economics 07:06 Zambia Trip Insights 09:34 Sitwi Project Option 11:48 Board and Leadership Changes 13:51 Permitting Status 14:20 Niger Asset Update https://atomiceagle.com.au/ ASX: AEU - OTCQB: AEUXF Press Releases Discussed: https://wcsecure.weblink.com.au/pdf/AEU/03089414.pdf https://wcsecure.weblink.com.au/pdf/AEU/03091279.pdf https://wcsecure.weblink.com.au/pdf/AEU/03083026.pdf https://wcsecure.weblink.com.au/pdf/AEU/03072398.pdf Sponsor Atomic Eagle pays MSE a United States dollar ten thousand per month coverage fee. The forward-looking statement disclaimer found in Atomic Eagle's most-recent company slide deck found at www.AtomicEagle.com.au applies to everything discussed in this interview. Mining Stock Education (MSE) offers informational content based on available data but it does not constitute investment, tax, or legal advice. It may not be appropriate for all situations or objectives. Readers and listeners should seek professional advice, make independent investigations and assessments before investing. MSE does not guarantee the accuracy or completeness of its content and should not be solely relied upon for investment decisions. MSE and its owner may hold financial interests in the companies discussed and can trade such securities without notice. MSE is biased towards its advertising sponsors which make this platform possible. MSE is not liable for representations, warranties, or omissions in its content. By accessing MSE content, users agree that MSE and its affiliates bear no liability related to the information provided or the investment decisions you make. Full disclaimer: https://www.miningstockeducation.com/disclaimer/

Most people assume that if a drug sits on the shelf at Costco or Walgreens, it must be pretty safe. But what if some of the most common over-the-counter (OTC) medications are among the riskiest drugs in America? On this vintage episode of Vitality Radio, Jared exposes the hidden dangers behind everyday pain relievers, sleep aids, and heartburn drugs—medicines that cause thousands of deaths every year when misused or taken long-term. You'll learn how a drug becomes “OTC,” what happens when pharmaceutical companies push for that switch, and why the FDA's approval process might not tell the whole story. Jared dives into the startling realities of PPIs like Prilosec, NSAIDs like ibuprofen, and acetaminophen (Tylenol)—uncovering their risks to the liver, kidneys, bones, and brain. He also discusses how marketing convinces consumers these drugs are harmless. Finally, Jared offers a resource for safe, natural alternatives for reflux, pain, inflammation, sleep, and immune support—options that nourish the body instead of depleting it. This episode will change the way you look at “harmless” OTC drugs and help you take real control of your health.Additional Information:#341: Your Digestive Health Supplement User's Guide. From IBS to Acid Reflux - Learn How to Balance Your Gut Health With Natural Products. #522: Q&A Show #5 - Jared Answers Your Questions About Energy and Sleep!#471: Boosting Your Immune System Ahead of Winter #553: Boswellia & Curcumin: Nature's Dream Team for Pain & Inflammation with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

The CPG Guys are joined in this  episode by Mike Wysong, CEO of CARE Pharmacies, Inc., a growing pharmacy network having served communities like your own for more than 64 years. CARE Pharmacies combines the quality of a trusted local pharmacy with the growth and stability of a national organization. With over 130 pharmacies nationwide and growing, CARE understands its patients, their special needs, prescriptions, local community health concerns, and the importance of personalized CARE - the building blocks to a healthy family and a strong local community.Follow Mike on LinkedIn at: https://www.linkedin.com/in/michael-wysong-a01626b/Follow CARE online at: https://www.carepharmacies.com/Mike answers these questions:What is the biggest lesson from those early days carrying the bag that you still lean on today as a CEO? What was that first fundamental structural or cultural shift you had to make to change that trajectory? How do you get independent owners to genuinely align on shared procurement, brand messages, and technology without stripping away that local entrepreneurship that makes them special? How does a cooperative structure create the necessary scale to let local community pharmacies win on price? From your seat, how can consumer product groups (CPGs) and OTC manufacturers better bridge those gaps to collaborate with a regional pharmacy layout like CARE? What are the top criteria or data-backed insights an emerging brand needs to bring to you today to earn shelf space over a legacy CPG giant? For emerging wellness or OTC brands listening to this show, what's your advice on the sales function—should they try to go it alone, or do they need to hire a specialized broker who truly understands regional drug chains? How are you helping independent pharmacies roll out complex tech, health informatics, and AI tools without eroding the high-touch, hyper-local intimacy that defines community pharmacy? As baby boomers choose to remain in their homes longer, how does the role of the community pharmacy transform from a simple script dispensary into an essential connector of the home health ecosystem? How critical is having a real-time view of inventory and fulfillment data to protecting your owners' bottom lines? As a board member and past chair of the NACDS, what is the most urgent story the industry needs to keep telling to protect its clinical and commercial relevance? What is the single biggest blind spot that corporate CPG executives have when they try to partner with independent, community-based retail networks? CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comSheCOMMERCE Website: https://shecommercepodcast.com/Rhea Raj's Website: http://rhearaj.comLara Raj in Katseye: https://www.katseye.world/DISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

On this episode of This Week in Pharmacy, we examine three major forces shaping healthcare today: the global impact of conflict on health security, the continued evolution of personalized specialty pharmacy care, and the over-the-counter products patients rely on most.   We open the show with Aman Gupta, Managing Partner, Asia-Pacific at SPAG FINN Partners, and contributor author at MedikaLife. Aman joins TWIRx to discuss his latest MedikaLife article, which argues that global conflict is quietly undermining health security by redirecting funding, attention, and infrastructure away from healthcare and toward defense priorities.   As military spending rises, health systems—especially in low- and middle-income countries—face growing pressure from shrinking access, rising costs, workforce shortages, disrupted supply chains, weakened disease surveillance, and reduced emergency preparedness. Conflicts in Ukraine, Gaza, and Sudan demonstrate how attacks on healthcare systems, displacement, malnutrition, and shortages of essential medicines can rapidly turn health access into a survival issue. Aman urges policymakers to treat health as strategic security infrastructure, not as a secondary social expense.   TWIRx also gives a special shout out to the Indian Pharmaceutical Association, recognizing its continued leadership and advocacy for the pharmacy profession.   Next, we welcome Dr. Chris Antypas, PharmD, with Perigon Pharmacy 360, for a discussion on how specialty pharmacy is becoming increasingly personalized. As complex therapies continue to advance, pharmacists are playing a critical role in ensuring medications and treatment plans are customized to optimize patient care. We explore how technology, workflow processes, clinical expertise, and pharmacists who deeply understand specific disease states are essential to successful specialty pharmacy outcomes.   To wrap up the episode, returning guest Shanley Chien Pierce, Senior Editor, Health at U.S. News & World Report, joins us to review the latest OTC medicine and health product evaluations. Top-rated products include Children's Delsym for coughs, Unisom for sleep, and Pedialyte for electrolytes, along with skincare favorites such as La Roche-Posay for retinol and Aquaphor for lip balm.   For the full list covering more than 128 categories, visit the U.S. News Best OTC Medicine & Health Products rankings.   Sponsored by Perigon Pharmacy 360 Listen & Subscribe Stay connected with This Week in Pharmacy and the Pharmacy Podcast Network for conversations with pharmacy leaders, healthcare innovators, policy experts, and industry voices shaping the future of care.

NEW PARTNERSHIPS (both are legit)Rice ‘N Grinds (Pride Foods) – 10% off w/ code TTMMegaFit Meals - 10% off w/ code TTMToday's Q&As: 00:00:00 - Intro 00:02:42 - Espresso vs regular coffee 00:05:00 - Is doing bodyweight lifts daily adding too much volume? 00:07:15 - Are weighted movements better for building abs? 00:11:58 - PEDs in the SOF pipeline / career 00:20:13 - Struggling to hit carb targets 00:26:41 - Improving push-up performance for SFAS 00:28:50 - Managing Army PT + hard training 00:33:45 - Travel during an SF career 00:35:59 - Lowering stress/cortisol as a hybrid athlete 00:47:11 - Thoughts on stretching post run? 00:48:57 - AFT prep with one month to go 00:51:55 - Using Ruck | Run | Lift for ultras 00:53:13 - Reason for OTC failure 00:55:53 - Are heart rate monitors necessary? 00:57:57 - Using straps while training for selection 01:04:18 - Mindset for injuries 01:06:56 - Flatland vs hills for rucking 01:08:17 - Is it worth cutting at 18% body fat if I can run a sub 35-min five-mile relatively easy for SFAS? 01:10:34 - Are there plans to make the self-development guide from the new SFAS plan available standalone? 01:11:36 - Eating back workout calories while cutting—Questions? Look for bi-weekly Q&A on my stories. I'll answer your questions on IG and here on the podcast.—New SFAS Program (includes 59-page SFAS Personal Dev Guidebook) New Running Program: TTM Run AdvancedNew Selection Prep Program: Ruck | Run | Lift New Hybrid Program: Jacked Gazelle 3.0Ebook: SOF Selection Recovery & Nutrition Guide—TrainHeroic Team Subscription: T-850 Rebuilt (try a week for free!)—PDF programs2 & 5 Mile Run Program - run improvement program w/ strength workKickstart- beginner/garage gym friendlyTime Crunch- Workouts for those short on timeHypertrophy- intermediate/advancedJacked Gazelle- Hybrid athleteJacked Gazelle 2.0 - Hybrid athleteSFAS Prep- Special forces train-up—Rice ‘N Grinds (Pride Foods) – 10% off w/ code TTMMegaFit Meals - 10% off w/ code TTM—Let's connect:Newsletter Sign UpIG: terminator_trainingYoutubeWebsiteSubstack

New triple hormone receptor agonist shows significant weight loss; hepatitis delta virus treatment gains accelerated approval; acne gel gains OTC designation; constipation treatment expanded to include younger patients; and the FDA extends review for camizestrant in advanced breast cancer.

This episode of The European Market Brief dives deep into the rapidly evolving world of credit derivatives and fixed income trading. Mark Longo is joined by Russell Rhoads ("Dr. VIX"), Natesh Pothalingam from Bloomberg, and Chris Dopp from Eurex to explore the explosive growth in listed credit index futures, the impact of inflation and geopolitical volatility on the credit markets, and why institutional and retail traders alike are increasingly embracing credit products. The panel discusses: Why credit index futures are gaining traction How rising rates and inflation fears are reshaping fixed income markets The evolution of European and global credit trading Why listed credit products may be more efficient than ETFs or OTC products Retail and "pro-tail" access to credit markets The future of sector-based and geographically expanded credit products Why liquidity and capital efficiency are driving adoption Plus: insights into high yield, investment grade credit, emerging markets, systematic trading flows, and the growing role of credit derivatives in modern portfolio management.

On this episode of This Week in Pharmacy, we examine two major forces reshaping the profession: the unfinished business of pharmacist provider status and the legal landscape around direct-to-consumer pharmaceutical distribution. In part one, Erik Abel, PharmD, MBA, discusses his May 2026 analysis, “So Pharmacists Want to Be a Provider: Where the Profession Lost Its Way and Perhaps a Path to Get Back.” Abel argues that pharmacy's provider-status challenge is not a lack of clinical evidence, but a lack of operational infrastructure: credentialing, payer contracting, revenue cycle management, interoperability, and scalable business models. In part two, Darshan Kulkarni, PharmD, Esq., joins the show to discuss direct-to-consumer pharmaceutical distribution, legal risk, regulatory scrutiny, telehealth-linked prescribing, manufacturer strategy, and what pharmacists need to understand as drug distribution moves closer to the patient. This week in pharmacy news, Pittsburgh-area pharmacies continue to face uneven access to Adderall and other ADHD medications, years after the FDA first identified shortages in 2022. Patients are still calling multiple pharmacies, switching medications, rationing doses, or going without treatment as availability varies by dosage, formulation, manufacturer, and wholesaler. Pharmacists are also using medication therapy management to protect older adults from preventable medication-related harm. MTM reviews can identify risky prescriptions and OTC products, including diphenhydramine, duplicate therapies, drug interactions, and long-term proton pump inhibitor use that may need reassessment. In 340B news, CVS Health is facing federal lawsuits from major health systems alleging CVS Specialty and WellPartner improperly retained approximately $250 million in savings that should have gone back to covered entities. The litigation adds pressure to debates over PBM integration, contract pharmacy arrangements, and 340B transparency. On Capitol Hill, lawmakers are pressing the Department of Defense to commit to annual audits of the TRICARE pharmacy contract as concerns continue around PBM conflicts of interest, reimbursement practices, network adequacy, and access for independent and community pharmacies.

PWTorch editor Wade Keller is joined by PWTorch's Chris Maitland. They discuss the Roman Reigns-Jacob Fatu fallout from Backlash, the "Fatu!" Chants before "OTC!" chants and how this feud is illustrative of a need for patience but also weaknesses in WWE's culture of presentation and structure that undercuts the stories they intend to tell with their top stars too often. They also talk with an on-site correspondent who attended in Knoxville and relays crowd reactions and also non-Raw matches. They also have chat and live caller interactions throughout the show exploring various key matches and segments and themes.Become a supporter of this podcast: https://www.spreaker.com/podcast/wade-keller-pro-wrestling-post-shows--3275545/support.

North Korea isn't just hacking crypto anymore, it's studying it, infiltrating it, and turning DeFi's weakest links into a state-run revenue machine. This time around, Ryan and David sit down with Ari Redbord of TRM Labs to unpack the Drift hack, the $6B DPRK crypto crime machine, how stolen funds move through THORChain, Bitcoin, OTC desks, and Chinese laundering networks, and why the fightback may require everything from better DeFi security to real-time Beacon alerts and offensive cyber. ---